Article Details
Retrieved on: 2024-11-27 14:41:13
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Syntara's drug development focus on addressing fibrotic and rare diseases like myelofibrosis and cystic fibrosis. It highlights SNT-5505's potential in transforming and healing conditions like pulmonary fibrosis through clinical trials, reflecting the tags and the healing concept.
Article found on: www.livewiremarkets.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here